Cargando…

Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy

Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and com...

Descripción completa

Detalles Bibliográficos
Autor principal: Pająk, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138518/
https://www.ncbi.nlm.nih.gov/pubmed/35625738
http://dx.doi.org/10.3390/biomedicines10051001
_version_ 1784714642152488960
author Pająk, Beata
author_facet Pająk, Beata
author_sort Pająk, Beata
collection PubMed
description Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a ‘breakthrough’. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy.
format Online
Article
Text
id pubmed-9138518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91385182022-05-28 Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy Pająk, Beata Biomedicines Review Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a ‘breakthrough’. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy. MDPI 2022-04-26 /pmc/articles/PMC9138518/ /pubmed/35625738 http://dx.doi.org/10.3390/biomedicines10051001 Text en © 2022 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pająk, Beata
Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title_full Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title_fullStr Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title_full_unstemmed Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title_short Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
title_sort looking for the holy grail—drug candidates for glioblastoma multiforme chemotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138518/
https://www.ncbi.nlm.nih.gov/pubmed/35625738
http://dx.doi.org/10.3390/biomedicines10051001
work_keys_str_mv AT pajakbeata lookingfortheholygraildrugcandidatesforglioblastomamultiformechemotherapy